Overview

A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection

Status:
Completed

Trial end date:
2016-10-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and efficacy of ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin in US veterans with genotype 1 chronic hepatitis C virus infection.

Phase:

Phase 3

Details

Lead Sponsor:

AbbVie

Treatments:

Ribavirin
Ritonavir